



GOVERNMENT OF GUAM



DEPARTMENT OF PUBLIC HEALTH and SOCIAL SERVICES

DIPATTAMENTON SALUT PUPBLEKO YAN SETBISION SUSIAT

123 Chalan Kareta, Mangilao, Guam 96913-6304

FELIX P. CAMACHO
Governor

J. PETER ROBERTO, ACSW
Director

MICHAEL W. CRUZ, M.D.
Lieutenant Governor

CLINICAL ADVISORY

Novel H1N1 Influenza Vaccine

September 2, 2009

When is it expected that the novel H1N1 vaccine will be available?

The novel H1N1 vaccine is expected to be available in mid to late October.

Will the seasonal flu vaccine also protect against the novel H1N1 flu?

The seasonal flu vaccine is not expected to protect against the novel H1N1 flu.

Can the seasonal vaccine and the novel H1N1 vaccine be given at the same time?

It is anticipated that seasonal flu and novel H1N1 vaccines may be administered on the same day. However, we expect the seasonal vaccine to be available earlier than the H1N1 vaccine.

Who will be recommended to receive the 2009 H1N1 vaccine?

CDC's Advisory Committee on Immunization Practices (ACIP) has recommended that certain groups of the population receive the novel H1N1 vaccine when it first becomes available.

These target groups include:

- **Pregnant women**
- **People who live with or care for children younger than 6 months of age,**
- **Healthcare and emergency medical services personnel,**
- **Persons between the ages of 6 months and 24 years old**
- **People 25 through 64 years of age who are at higher risk for novel H1N1 because of chronic health disorders or compromised immune systems.**

Availability and demand can be unpredictable. There is some possibility that initially the vaccine will be available in limited quantities.

In this setting, the committee recommended that the following groups receive the vaccine before others:

- **Pregnant women,**
- **People who live with or care for children younger than 6 months of age,**
- **Health care and emergency medical services personnel with direct patient contact**
- **Children 6 months through 4 years of age, and children 5 through 18 years of age who have chronic medical conditions.**

It is recommended that once the demand for vaccine for these target groups has been met at the local level, programs and providers should begin vaccinating everyone from ages 25 through 64 years.

Current studies indicate the risk for infection among persons age 65 or older is less than the risk for younger age groups. Therefore, as vaccine supply and demand for vaccine among younger age groups is being met, programs and providers should offer vaccination to people over the age of 65.